Development and Validation of a Rapid and Simple LC-MS/MS Method for Quantification of Vemurafenib in Human Plasma: Application to a Human Pharmacokinetic Study

摘要

Background: Vemurafenib (Zelboraf) is a new tyrosine kinase inhibitor that selectively targets activated BRAF V600E gene and is indicated for the treatment of advanced BRAF mutation-positive melanoma. We developed a simple method for vemurafenib quantification using liquid chromatography-tandem mass spectrometry. A stability study of vemurafenib in human plasma was also performed.